Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Novo Nordisk says the US FDA has approved a once daily pill version of Wegovy, described as the first approved pill of its kind The company said trials showed average weight loss of 16.6%, with about a third of roughly 1,300 participants losing 20% or more Novo Nordisk expects a US launch in early January 2026, with investors pushing shares up sharply after the announcement amid strong competition in the weight loss market US regulators have approved an oral version of Wegovy for chronic weight management, giving Novo Nordisk the first daily pill in this drug class cleared for obesity treatment, according to the company and US media reports
When used thoughtfully and with medical guidance, they can be a helpful tool
Read our verification methodology for what each status means, and our editorial policy for how placement is kept separate from verification.
Settling may occur
Listen to their perspective, ask follow-up questions, and be open to other options for managing your weight
US$ 29.76
US$ 29.02
US$ 27.77
